Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial

Aug 28, 2018

Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial. The study achieved its primary endpoint at the first pre-specified interim analysis, with ...

Read More

Pfizer’s Innovative drug IBRANCE gets China approval

Aug 9, 2018

World’s First Kinase 4/6 (CDK 4/6) Inhibitor and Only Innovative Breakthrough Therapy for Advanced Breast Cancer in China over Past Ten Years Pfizer China announced that the China National Drug Administration (CNDA) has granted approval of IBRANCE® (palbociclib) on July ...

Read More

Eisai inks deal with Taiwan’s CY Biotech

Aug 9, 2018

The deal grants CY Biotech with exclusive development and marketing rights for its anti-obesity agent lorcaserin in China Japan-based Eisai recently announced that it has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent ...

Read More